scPharmaceuticals

scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

scPharmaceuticals reports Q4 loss, sees growth potential with FUROSCIX

scPharmaceuticals' financials show investment in the FUROSCIX launch, with a net loss reported for Q4 2022 and the full year.
FUROSCIX's commercial success, distribution partnerships, and evolving physician perceptions are key strengths for the company.
Challenges lie in reimbursement processes, achieving target co-pays, and aligning on optimal FUROSCIX use timing among doctors.
Opportunities include the substantial market potential, targeted outreach to hospitals, and driving prescriptions through in-services.

scPharmaceuticals reports mixed Q1 results, FUROSCIX shows promising market reception

scPharmaceuticals reported mixed financials with strong revenue but a net loss in Q1 2023.
FUROSCIX's success in the market and positive feedback position it well for future growth.
Challenges exist in managing expenses and securing broader coverage for the treatment.
Opportunities lie in expanding patient access, improving authorization rates, and driving revenue growth.

scPharmaceuticals reports $1.6M Q2 revenue, eyes FDA filing expansion

scPharmaceuticals (SCPH) reported mixed financial results for Q2, with strong revenue but a net loss. The company is focused on expanding FUROSCIX's market reach, improving gross to net discount, and enhancing brand awareness through marketing efforts. Anticipated FDA filing and plans for indication expansion signal growth potential.

scPharmaceuticals reports stellar Q3 performance, eyes market expansion opportunities

scPharmaceuticals delivered robust financial results in Q3 2023, driven by strong revenue growth and improved gross profit margins.
Strategic initiatives to expand market reach and access to FUROSCIX position the company for sustained growth and market penetration.
While facing challenges in pricing dynamics and regulatory expansions, scPharmaceuticals holds significant opportunities for growth and value creation.

scPharmaceuticals reports strong Q4 earnings and eyes market expansion

scPharmaceuticals showcased robust financial performance and strategic growth initiatives in Q4 2023, driven by FUROSCIX sales.
While facing market complexities and operational challenges, the company maintains a strong cash position and optimistic outlook for future initiatives.
Opportunities lie in market access negotiations, streamlined regulatory processes, and expanding product coverage, positioning scPharmaceuticals for continued success.

scPharmaceuticals reports Q1 challenges but remains optimistic for 2024

scPharmaceuticals faced challenges in Q1 due to a cyber attack and increased expenses, but showed resilience with positive trends in FUROSCIX utilization and growth initiatives. The company remains optimistic for continued momentum and life cycle initiatives in 2024.

scPharmaceuticals reports robust Q2 performance and regulatory wins

scPharmaceuticals delivered strong financial performance and regulatory milestones in Q2 2024, positioning the company for growth.
While facing operational challenges and competitive pressures, the company's strategic strengths and opportunities offer avenues for future success.
With a focus on innovation, market expansion, and financial stability, scPharmaceuticals is poised for continued growth and value creation.
Investors can be optimistic about scPharmaceuticals' progress and potential in the pharmaceutical market based on the Q2 performance and strategic initiatives.

scPharmaceuticals reports revenue growth and strategic advancements in Q3

scPharmaceuticals demonstrated revenue growth and strategic advancements in Q3 2024, underpinned by strong FUROSCIX sales and key initiatives.
While facing challenges such as ongoing losses and pricing dynamics, the company's focus on innovation and commercial progress positions it well for future growth.
With opportunities in seasonal demand, market expansion, and a solid financial base, scPharmaceuticals is poised for continued development and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BURLINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will participate in two upcoming investor conferences.

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

Company anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

Q3 earnings report shows positive performance, with Furoscix net sales exceeding consensus estimates. scPharmaceuticals' progress in securing payer coverage and IDN agreements is driving confidence in its prospects. The company's healthy financial position and potential market opportunity for Furoscix make it an undervalued investment.

scPharmaceuticals Q3 Earnings: Cruising Toward Success

Archer Aviation

Among various strategies and methods used in stock trading, shorting is a daring one. Seen as a high-risk approach, it involves borrowing and selling stocks, betting on their price decline.

Short squeeze alert for November 9th: 2 stocks that could surge

scPharmaceuticals Inc (NASDAQ:SCPH ) Q3 2023 Earnings Call Transcript November 8, 2023 4:30 PM ET Company Participants PJ Kelleher - LifeSci Advisors John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President, Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Nik Gasic - Leerink Partners Douglas Tsao - H.C. Wainwright Naz Rahman - Maxim Group Chase Knickerbocker - Craig-Hallum Capital Group Operator Thank you for standing by.

scPharmaceuticals Inc (SCPH) Q3 2023 Earnings Call Transcript

Generated net FUROSCIX® revenue of $3.8 million Ended Q3 2023 with cash, cash equivalents and short-term investments of $90.2 million Company to host investor conference call and webcast today, Wednesday, November 8, at 4:30pm ET BURLINGTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the third quarter ended September 30, 2023, and provided a business update.

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

BURLINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m.

scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

BURLINGTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on October 2, 2023, the Compensation Committee of scPharmaceuticals' board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 52,500 shares of its common stock to 14 new employees comprised of sales representatives.

scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Positive FDA feedback for Furoscix's label expansion into chronic kidney disease signals the potential for significant market growth. Introduction of a higher concentration auto-injector formulation of Furoscix could reduce costs and enhance patient convenience. Q2 earnings show encouraging market momentum for Furoscix, with continued demand and growth in prescribers.

scPharmaceuticals: Furoscix, Charting A Bright Future With FDA's Nod For CKD

Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients

scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives

Today, we take our first look at scPharmaceuticals Inc., which has received positive analyst commentary but has a large short position in the stock. The company just launched its franchise product FUROSCIX in February of this year and management believes it has huge potential. Analysts expect sales to reach nearly $40 million in FY2024, but the company is projected to continue experiencing losses.

Sizing Up scPharmaceuticals

BURLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13 at 10:00 am ET. In addition to the fireside chat, Mr. Tucker will also be meeting with investors.

scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants PJ Kelleher - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President, Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Glen Santangelo - Jefferies Stacy Ku - TD Cowen Doug Tsao - H.C. Wainwright Naz Rahman - Maxim Group Operator Good day and welcome to the scPharmaceuticals Second Quarter 2023 Earnings Conference Call.

scPharmaceuticals Inc. (SCPH) Q2 2023 Earnings Call Transcript

Generated net FUROSCIX® revenue of $1.6 million Ended Q2 2023 with cash, cash equivalents and short-term investments of $102.9 million Company to host investor conference call and webcast today, Thursday, August 10, at 4:30pm ET BURLINGTON, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the second quarter ended June 30, 2023, and provided a business update.

scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

BURLINGTON, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m.

scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Company also announces issuance of key patents covering development of alternate formulations of furosemide Company also announces issuance of key patents covering development of alternate formulations of furosemide

scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion

The heavy selling pressure might have exhausted for scPharmaceuticals, Inc. (SCPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

scPharmaceuticals, Inc. (SCPH) Loses -21.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

scPharmaceuticals' Furoscix dose-filling rates increased by 55% month over month in May. Despite the lower figures than market expectations, SCPH stock price has fallen, but we expect an inflection point in 2H 2023 as more coverage is added. Risks to the company's growth and stock value include potential disappointment in future script numbers, delays in obtaining broad preferred formulary status for Medicare Part D plans, issues with prescriber education and adoption, and difficulties in expanding the sales force.

scPharmaceuticals: Oversold Territory, Drug Launch Still Looks Robust

BURLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it expects to be added to the small cap Russell 2000® and broad market Russell 3000® Indexes at the conclusion of the Russell US Indexes annual reconstitution, effective when the US market opens on June 26, 2023, according to a preliminary list of additions posted on May 19, 2023.

scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes

BURLINGTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference, which is being held June 7-9 in New York.

scPharmaceuticals to Present at the Jefferies Healthcare Conference

SCPH's Furoscix, despite just launching, defied street consensus with an impressive $2.1M revenue in 1Q23, indicating a promising ramp trajectory. Witnessing a substantial increase in Furoscix's prescriptions and robust demand, supported by a growing sales force, hints at a sound growth strategy.

scPharmaceuticals: Furoscix Firing On All Cylinders In Q1, Bullish Than Ever

ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.28 per share a year ago.

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

Announced launch and commercial availability of FUROSCIX® on February 20 th Generated net FUROSCIX revenue of $2.1 million Ended Q1 2023 with cash, cash equivalents and short-term investments of $116.1 million Company to host investor conference call and webcast today, Wednesday, May 10, at 4:30pm ET BURLINGTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the first quarter ended March 31, 2023, and provided a business update.

scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

BURLINGTON, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m.

scPharmaceuticals to Announce First Quarter 2023 Financial Results on Wednesday, May 10, 2023

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants PJ Kelleher - LifeSci Advisors John Tucker - CEO Rachael Nokes - CFO Steve Parsons - SVP, Commercial Conference Call Participants Glen Santangelo - Jefferies Nik Gasic - SVB Securities Stacy Ku - Cowen Douglas Tsao - H.C. Wainwright Nazibur Rahman - Maxim Group Greetings, and welcome to the scPharmaceuticals Fourth Quarter and Full Year 2022 Earnings Conference Call.

News for scPharmaceuticals Stock (SCPH)